Thu, May 15, 12:37 PM (32 days ago)
**Lantern Pharma Inc. (LTRN) Q1 2025 Financial Summary** **Financial Health:** - **Cash Position:** Cash and cash equivalents decreased to $6.38 million from $7.51 million in Q1 2024. - **Marketable Securities:** Decreased to $13.34 million from $16.50 million in Q1 2024. - **Working Capital:** Approximately $16.54 million, indicating sufficient short-term liquidity. - **Total Assets:** $21.10 million, down from $25.57 million in Q1 2024. - **Total Liabilities:** $4.32 million, slightly decreased from $4.38 million in Q1 2024. **Performance Metrics:** - **Revenue:** No revenue recognized for Q1 2025 and Q1 2024. - **Net Loss:** $4.54 million, improved from $5.44 million in Q1 2024. - **Operating Expenses:** $4.77 million, down from $5.73 million in Q1 2024. - **R&D Expenses:** $3.26 million, decreased from $4.25 million in Q1 2024. - **G&A Expenses:** $1.51 million, slightly increased from $1.48 million in Q1 2024. - **Profit Margins:** Negative, with a net loss per share of $0.42, improved from $0.51 in Q1 2024. **Cash Flow:** - **Operating Activities:** Net cash used was $4.38 million, increased from $3.07 million in Q1 2024. - **Investing Activities:** Net cash provided was $3.24 million, improved from a use of $556,000 in Q1 2024. - **Financing Activities:** No cash flows in Q1 2025, compared to $54,716 from warrant exercises in Q1 2024. **Earnings Changes:** - **Net Loss Improvement:** Net loss decreased by approximately $904,000 compared to Q1 2024. - **Operating Expenses Reduction:** Total operating expenses decreased by $958,000, primarily due to reduced R&D expenses. **Quarterly Performance Discussion:** - **Operational Focus:** Continued development of three clinical-stage oncology drug candidates (LP-300, LP-184, LP-284) and an ADC program. - **Strategic Initiatives:** Leveraging the RADR® platform for drug development and patient response prediction. - **Future Operations Impact:** Plans to explore periodic capital raises, grant funding, and potential commercial credit facilities to support capital needs. **Trends and Uncertainties:** - **Market Risks:** Exposure to interest rate sensitivity and potential foreign currency losses. - **Operational Risks:** Dependence on clinical trial outcomes, regulatory approvals, and successful fundraising. - **Future Outlook:** Expects to continue incurring significant operating losses as it advances its drug candidates through clinical trials and seeks regulatory approval. **Future Operations Impact:** - **Capital Requirements:** Believes existing cash, cash equivalents, and marketable securities will fund operations for at least 12 months from Q1 2025. - **Funding Needs:** Will require substantial additional funding in the near future to support ongoing and future clinical trials and potential commercialization efforts.